News headlines about Zafgen (NASDAQ:ZFGN) have trended somewhat positive on Monday, according to Accern Sentiment Analysis. The research group ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Zafgen earned a news sentiment score of 0.07 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 46.9390024274984 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Several research firms recently weighed in on ZFGN. Zacks Investment Research raised shares of Zafgen from a “hold” rating to a “buy” rating and set a $3.75 target price for the company in a research note on Tuesday, September 19th. ValuEngine raised shares of Zafgen from a “strong sell” rating to a “sell” rating in a research note on Thursday, July 6th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the company’s stock. Zafgen currently has a consensus rating of “Hold” and an average price target of $6.38.

Zafgen (NASDAQ:ZFGN) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.52) by $0.03. During the same period in the prior year, the company posted ($0.55) EPS.

In related news, insider Dennis D. Kim purchased 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 11th. The stock was acquired at an average price of $3.39 per share, for a total transaction of $33,900.00. Following the completion of the acquisition, the insider now owns 21,443 shares of the company’s stock, valued at approximately $72,691.77. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 21.20% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This story was first published by Watch List News and is owned by of Watch List News. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at

About Zafgen

Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.

Insider Buying and Selling by Quarter for Zafgen (NASDAQ:ZFGN)

Receive News & Ratings for Zafgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.